Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 110
- Registration Number
- NCT00447967
- Locations
- 🇬🇷
State General Hospital of Larissa, Larissa, Greece
🇬🇷"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece
🇬🇷University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
- Conditions
- Stage IVA Pancreatic CancerAdenocarcinoma of the PancreasStage III Pancreatic Cancer
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- National Institutes of Health Clinical Center (CC)
- Registration Number
- NCT00020345
- Locations
- 🇺🇸
Radiation Oncology Branch, Bethesda, Maryland, United States
🇺🇸Surgery Branch, Bethesda, Maryland, United States
Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer
- Conditions
- Colorectal CancerMetastatic Cancer
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2011-09-02
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 100
- Registration Number
- NCT00438737
- Locations
- 🇫🇷
Hopital Ambroise Pare, Boulogne, France
Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery
- Conditions
- Metastatic CancerPancreatic Cancer
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Goshen Health System
- Target Recruit Count
- 20
- Registration Number
- NCT00436267
- Locations
- 🇺🇸
Center for Cancer Care at Goshen General Hospital, Goshen, Indiana, United States
Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- Target Recruit Count
- 2000
- Registration Number
- NCT00433420
5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)
- Conditions
- Neoplasm MetastasisColorectal Cancer
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- PD Dr. med. Volker Heinemann
- Target Recruit Count
- 568
- Registration Number
- NCT00433927
- Locations
- 🇩🇪
University of Munich - Klinikum Grosshadern, Munich, Germany
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- Drug: lapatinibBiological: trastuzumabDrug: paclitaxelDrug: epidoxorubicinDrug: fluorouracilDrug: cyclophosphamide
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 121
- Registration Number
- NCT00429299
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- NSABP Foundation Inc
- Registration Number
- NCT00427570
Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 1158
- Registration Number
- NCT00427310
Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer
- Conditions
- Esophageal Cancer
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 43
- Registration Number
- NCT00425425
- Locations
- 🇩🇪
Universitaetsklinikum Giessen und Marburg GmbH - Marburg, Marburg, Germany
🇩🇪Charite University Hospital - Campus Virchow Klinikum, Berlin, Germany
🇩🇪Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.